Cargando…
Suppression of murine tumour growth through CD8(+) cytotoxic T lymphocytes via activated DEC‐205(+) dendritic cells by sequential administration of α‐galactosylceramide in vivo
Cancer immunity is mediated through the effective priming and activation of tumour‐specific class I MHC molecule‐restricted CD8(+) cytotoxic T lymphocytes (CTLs). DEC‐205(+) dendritic cells (DCs) can cross‐present the epitope(s) of captured tumour antigens associated with class I MHC molecules along...
Autores principales: | Kogo, Hideki, Shimizu, Masumi, Negishi, Yasuyuki, Uchida, Eiji, Takahashi, Hidemi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461099/ https://www.ncbi.nlm.nih.gov/pubmed/28294313 http://dx.doi.org/10.1111/imm.12733 |
Ejemplares similares
-
α‐Galactosylceramide‐activated murine NK1.1(+) invariant‐NKT cells in the myometrium induce miscarriages in mice
por: Ichikawa, Tomoko, et al.
Publicado: (2016) -
Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells
por: Moriya, Keiichi, et al.
Publicado: (2010) -
Antigen Targeting of Porcine Skin DEC205(+) Dendritic Cells
por: Melgoza-González, Edgar Alonso, et al.
Publicado: (2022) -
Induction of tumor-specific CD8(+) cytotoxic T lymphocytes from naïve human T cells by using Mycobacterium-derived mycolic acid and lipoarabinomannan-stimulated dendritic cells
por: Tomita, Yuji, et al.
Publicado: (2019) -
The PGRMC1 Antagonist AG-205 Inhibits Synthesis of Galactosylceramide and Sulfatide
por: Wang-Eckhardt, Lihua, et al.
Publicado: (2021)